Plain-English translation of NCT04731558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Doctors know that patients undergoing liver surgery face a risk of dangerous blood clots after the operation. This trial is testing whether starting low-molecular weight heparin—a blood clot prevention medication—before surgery works better and safer than starting it after surgery. The goal is to find the best timing for this medication to protect patients without increasing bleeding complications.
Right now, doctors disagree about when to start blood clot prevention in liver surgery patients. Some medical guidelines recommend starting before surgery, while others recommend waiting until after. This matters because liver surgery carries special risks: starting the medication too early might cause dangerous bleeding, but starting it too late might allow blood clots to form. This trial exists to settle this important question with solid evidence.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive blood clot prevention medication either before or after your scheduled liver surgery. You will follow your surgical team's standard care plan, with the main difference being the timing of when the prevention medication begins. The study will track how well the medication prevents blood clots and whether it affects bleeding or other complications during your recovery.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Finland